Adam J DiPippo
Overview
Explore the profile of Adam J DiPippo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
215
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bruner S, DiPippo A, Rausch C
Leuk Lymphoma
. 2024 Oct;
66(2):352-354.
PMID: 39374372
No abstract available.
2.
McGhie A, Lee J, Ferrajoli A, DiPippo A
Leuk Lymphoma
. 2023 Mar;
64(5):1050-1053.
PMID: 36891585
No abstract available.
3.
Abbas H, Sun H, Pierce S, Kanagal-Shamanna R, Li Z, Yilmaz M, et al.
Blood Adv
. 2022 Apr;
7(5):828-831.
PMID: 35405739
No abstract available.
4.
Rausch C, DiPippo A, Jiang Y, DiNardo C, Kadia T, Maiti A, et al.
Clin Infect Dis
. 2022 Mar;
75(9):1503-1510.
PMID: 35325094
Background: Multiple factors influence the choice of primary antifungal prophylaxis (PAP) in patients with acute myeloid leukemia (AML) undergoing remission induction chemotherapy (RIC) given the recent incorporation of targeted leukemia...
5.
DiPippo A, Wilson N, Pemmaraju N
Expert Rev Hematol
. 2021 Oct;
14(11):993-1004.
PMID: 34607517
Introduction: Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive hematologic malignancy with historically poor outcomes for patients, often refractory to traditional chemotherapy. Recent research has focused on...
6.
DiPippo A, McDaneld P, Tverdek F, Kontoyiannis D
Antimicrob Agents Chemother
. 2021 Sep;
65(12):e0123021.
PMID: 34570643
Posaconazole (POS) appears to have dose-proportional pharmacokinetics; however, there is a paucity of real-life data. We retrospectively evaluated 67 patients with hematologic cancer who had POS dose increases from 300 ...
7.
Rausch C, DiNardo C, Maiti A, Jammal N, Kadia T, Marx K, et al.
Cancer
. 2021 Apr;
127(14):2489-2499.
PMID: 33793970
Background: Venetoclax (VEN) combined with the hypomethylating agent (HMA) azacitidine improves survival in patients aged ≥75 years with newly diagnosed acute myeloid leukemia (AML). VEN and HMA treatment can result...
8.
Diao S, Nichols E, DiNardo C, Konopleva M, Ning J, Qiao W, et al.
Am J Hematol
. 2020 Dec;
96(3):E65-E68.
PMID: 33259075
No abstract available.
9.
Frei M, Aitken S, Jain N, Thompson P, Wierda W, Kontoyiannis D, et al.
Leuk Lymphoma
. 2020 Jun;
61(10):2488-2491.
PMID: 32530347
No abstract available.
10.
Anastasopoulou A, DiPippo A, Kontoyiannis D
Mycoses
. 2020 May;
63(8):787-793.
PMID: 32458510
Background: Invasive mould infections (IMIs) are very rare in patients with lymphoid malignancies. However, IMIs, mostly due to Aspergillus species, have been increasingly reported in such patients receiving ibrutinib (IBR)....